Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.45 |
| ▸ | BRD4 | O60885 | 10/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12413817 | 0.90 | ERN1 (0.38) | ERN1BRD4PIK3CDPTGDR2LMNA | |
| SCHEMBL2285069 | 0.89 | ERN1 (0.43) | ERN1BRD4PIK3CDPTGDR2 | |
| SCHEMBL2146304 | 0.88 | ERN1 (0.36) | ERN1BRD4PIK3CDPTGDR2LMNA | |
| SCHEMBL2146302 | 0.88 | ERN1 (0.36) | ERN1BRD4PIK3CDPTGDR2LMNA | |
| SCHEMBL2146131 | 0.84 | ERN1 (0.41) | ERN1BRD4LMNAESR1ESR2 | |
| SCHEMBL13460258 | 0.84 | BRD4 (0.37) | ERN1BRD4PIK3CDPTGDR2LMNA | |
| SCHEMBL2282817 | 0.84 | ERN1 (0.43) | ERN1BRD4PIK3CDPTGDR2 | |
| SCHEMBL2283182 | 0.82 | ERN1 (0.42) | ERN1BRD4PIK3CDPTGDR2LMNA | |
| SCHEMBL2287848 | 0.82 | ERN1 (0.44) | ERN1BRD4PIK3CDPTGDR2LMNA | |
| SCHEMBL2146813 | 0.81 | BRD4 (0.36) | ERN1BRD4PIK3CDPTGDR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201555-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201555-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-08-18 | — | — | US | disclosed |
| US-20110201555-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-08-18 | — | — | US | disclosed |
| EP-2346824-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010031852-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010031852-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | KARO BIO AB (SE) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201555-A1 | NOVEL ESTROGEN RECEPTOR LIGANDS | ESR1, ESRRA, GPER1 | ERN1 384/4885BRD4 891/4885PIK3CD 4139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.